A Single-Center, Open-Label, Parallel Study to Investigate the Effects of Multiple Doses of Ketoconazole on the Pharmacokinetics of a Single Oral Dose of RO4602522 in Healthy Male Subjects
Latest Information Update: 13 Jun 2016
Price :
$35 *
At a glance
- Drugs Sembragiline (Primary) ; Ketoconazole
- Indications Alzheimer's disease; Seborrhoeic dermatitis
- Focus Pharmacokinetics
- Sponsors Roche
- 03 Dec 2012 Planned End Date (Dec 2012) added as reported by ClinicalTrials.gov.
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Nov 2012 New trial record